Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease

Trial Profile

Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Coronary artery disease
  • Focus Biomarker; Therapeutic Use
  • Acronyms ASSERT
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2016 Results of post hoc analysis of phase IIb ASSERT and ASSURE trials (n=51), presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 09 Nov 2015 Results from the post-hoc analysis of ASSERT, SUSTAIN and ASSURE trials presented at the American Society of Nephrology (ASN) Kidney Week conference, as per a Reservlogix corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top